Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China

• DOI: 10.1371/journal.pone.0134539
• Publication Date: 2015-08-19T17:57:11Z
• Authors: Lijun Gu; Yang Han; Yijia Li; Ting Zhu; Xiaojing Song; Ying Huang; Feifei Yang; Shuo Guan; Jing Xie; Jin Gohda; Noriaki Hosoya; Ai Kawana-Tachikawa; Wenjun Liu; George Fu Gao; Aikichi Iwamoto; Taisheng Li; Takaomi Ishida
• Keywords: Hepatitis B; Reverse-transcriptase inhibitor

In China, HIV-1-infected patients typically receive antiretroviral therapy (ART) that includes lamivudine (3TC) as a reverse-transcriptase inhibitor (RTI) (ART-3TC). Previous studies from certain developed countries have shown that, in ART-3TC, 3TC-resistant HBV progressively emerges at an annual rate of 15–20% coinfected with HIV-1 and HBV. This scenario China warrants investigation because >10% all HIV-infected are carriers. We measured the occurrence during ART-3TC for HIV-HBV coinfection also tested effect tenofovir disoproxil fumarate (TDF) used additional RTI (ART-3TC/TDF) cohort study China. obtained 200 plasma samples collected 50 Chinese (positive hepatitis B surface antigen) examined them prevalence by directly sequencing PCR products covered gene. divided into ART-3TC/TDF groups compared efficacy treatment incidence drug-resistance mutation between groups. HIV RNA DNA loads drastically decreased both group, breakthrough or insufficient suppression was observed 20% (10/50) after 96-week treatment, 8 these harbored mutants. By contrast, neither nor failure recorded group. All mutants emerged cases which were high baseline. Our results clearly demonstrated is associated emergence reduces to undetectable level. These findings support use TDF-based regimens